Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Comerica Bank

Comerica Bank lessened its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 69.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 16,134 shares of the company's stock after selling 37,055 shares during the quarter. Comerica Bank's holdings in Pacira BioSciences were worth $304,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in PCRX. PNC Financial Services Group Inc. raised its stake in Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after acquiring an additional 513 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Pacira BioSciences by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after purchasing an additional 918 shares during the last quarter. Sterling Capital Management LLC increased its position in shares of Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after purchasing an additional 1,208 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Pacira BioSciences by 5.6% in the 4th quarter. MetLife Investment Management LLC now owns 27,883 shares of the company's stock valued at $525,000 after purchasing an additional 1,471 shares during the last quarter. Finally, Caitlin John LLC boosted its position in shares of Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after purchasing an additional 1,776 shares during the period. Hedge funds and other institutional investors own 99.73% of the company's stock.

Analysts Set New Price Targets

PCRX has been the subject of a number of research reports. HC Wainwright boosted their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. Barclays increased their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Needham & Company LLC reduced their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and raised their price target for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Pacira BioSciences has a consensus rating of "Hold" and an average price target of $26.44.

Pacira BioSciences Price Performance

PCRX traded up $0.60 on Tuesday, hitting $26.75. 787,625 shares of the company were exchanged, compared to its average volume of 971,088. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.64. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm has a market capitalization of $1.24 billion, a P/E ratio of -13.18 and a beta of 0.56. The business's fifty day moving average is $24.96 and its 200 day moving average is $22.51.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.